GLS and cancer: Importantly, P198 shGTK‐KD cells treated with a GLS1 inhibitor, BPTES, were observed to have the lowest cell numbers among all the groups (Figure 3C), demonstrating that genetic targeting of GTK in combination with pharmacological inhibition of GLS1 accentuates cancer cell growth inhibition in vitro.